Tech Company Financing Transactions
BioRexis Pharmaceutical Funding Round
On 3/11/2004, BioRexis Pharmaceutical raised $30 million in Series B funding from Prism VentureWorks, Anthem Venture Partners and Gund Investment Corporation.
Transaction Overview
Company Name
Announced On
3/11/2004
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Proceeds Purpose
The funds raised in the Series B round will be used to advance BioRexis' pipeline of biopharmaceuticals through preclinical testing and clinical trials.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3400 Horizon Dr.
King of Prussia, PA 19406
USA
King of Prussia, PA 19406
USA
Phone
Website
Email Address
Not Recorded
Overview
BioRexis Pharmaceutical Corporation uses its unique fusion technology platform to enhance the half-life, efficacy and safety of therapeutic proteins and peptides.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David King
Browse more venture capital transactions:
Prev: 3/10/2004: Zalicus venture capital transaction
Next: 3/15/2004: ReproSource venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs